Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-Azacitidine Plus PD-1/PD-L1 Inhibitor in PD-1/PD-L1 Refractory Tumors
NCT07404332Phase 1Recruiting
- Start
- Feb 2026
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azacitidine in solid tumor. Primary endpoint: Incidence of dose-limiting toxicities. Started Feb 2026; status: recruiting.
02
Drugs
azacitidine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07404332.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07404332.